Articles
135
All (135)
SCI-E, SSCI, AHCI (118)
SCI-E, SSCI, AHCI, ESCI (127)
ESCI (9)
Scopus (124)
TRDizin (11)
Other Publications (4)
42. Sentinel lymph node biopsy with/without axillary dissection in clinically node-positive breast cancer after neoadjuvant chemotherapy
ANNALS OF SURGICAL ONCOLOGY
, vol.29, no.SUPPL 1, pp.69-70, 2022 (SCI-Expanded, Scopus)
65. Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
, vol.7, no.5, pp.1459-1464, 2014 (SCI-Expanded, Scopus)
72. 5-Flourouracil-Induced Encephalopathy in Parkinson's Disease
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, vol.22, no.1, pp.51-53, 2012 (SCI-Expanded, Scopus, TRDizin)
73. The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; multicenter observational study.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.16, no.4, pp.664-71, 2011 (SCI-Expanded, Scopus)
84. Primary breast mantle cell lymphoma with atypical relapse patterns.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.16, no.1, pp.181-2, 2011 (SCI-Expanded, Scopus)
90. A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.14, no.2, pp.309-11, 2009 (SCI-Expanded, Scopus)
102. Clinical outcome of node-negative (NN) breast cancer (BC) patients
JOURNAL OF CLINICAL ONCOLOGY
, vol.25, no.18, 2007 (SCI-Expanded, Scopus)
103. The role of adjuvant chemoradiotherapy (CRT) in Turkish patients with gastric carcinoma
JOURNAL OF CLINICAL ONCOLOGY
, vol.25, no.18, 2007 (SCI-Expanded, Scopus)
104. Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital
JOURNAL OF CLINICAL ONCOLOGY
, vol.25, no.18, 2007 (SCI-Expanded, Scopus)
115. Remaining controversies in the upfront management of advanced ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
, vol.14, pp.707-20, 2004 (SCI-Expanded, Scopus)
118. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Annals of oncology : official journal of the European Society for Medical Oncology
, vol.15, pp.211-7, 2004 (SCI-Expanded, Scopus)
119. Clinical features and adjuvant treatment outcomes of colon cancer (cc) in two outpatient populations of Knoxville, Tennessee and Istanbul, Turkey
ANNALS OF ONCOLOGY
, vol.15, pp.95, 2004 (SCI-Expanded, Scopus)
120. Treatment outcomes in non-small cell lung cancer (NSCLC) patients: Comparison between Marmara University, Istanbul, Turkey and Knoxville, Tennessee
ANNALS OF ONCOLOGY
, vol.15, pp.195-196, 2004 (SCI-Expanded, Scopus)
121. Clinical outcome of breast cancer (BC) patients (pts) with pT1N0M0 disease
ANNALS OF ONCOLOGY
, vol.15, pp.68, 2004 (SCI-Expanded, Scopus)
126. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
European journal of cancer (Oxford, England : 1990)
, vol.39, pp.1277-83, 2003 (SCI-Expanded, Scopus)
127. Neoplastic diseases prevalence in a turkish university hospital.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.8, no.1, pp.45-8, 2003 (Scopus)
131. Progress in systemic therapy for breast cancer
EUROPEAN JOURNAL OF CANCER
, vol.38, 2002 (SCI-Expanded, Scopus)
135. Endocarditis prophylaxis for transrectal prostatic biopsy
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
, vol.280, no.22, pp.1908, 1998 (SCI-Expanded, Scopus)
Papers Presented at Peer-Reviewed Scientific Conferences
55
2. Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases
Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024, (Summary Text)
3. Combined Analysis of the MF18-02/03 Neosentiturk Studies: Factors Predicting Recurrence in ycN0/ypN-positive Breast Cancer with Sentinel Lymph Node Biopsy - Or Targeted Axillary Dissection - Alone After Neoadjuvant Chemotherapy
24th Annual Meeting of The American Society of Breast Surgeons (ASBrS), Mississippi, United States Of America, 26 - 30 April 2023, (Summary Text)
8. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 June 2022, (Summary Text)
9. Clinical outcome and characteristics of Turkish breast cancer patients during SARSCov-2 pandemic: Single center experience.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 June 2022, (Summary Text)
12. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38, (Summary Text)
15. Clinical, Radiological and Pathological Findings in Breast Cancer Patients Younger than 30
Breastanbul 2018 3rd Breast Cancer Conference, İstanbul, Turkey, 11 - 13 October 2018, (Summary Text)
16. Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29, pp.104-105, (Summary Text)
18. High Ki67 levels are significantly correlated with 21-gene assay recurrence scores
10th European Breast Cancer Conference (EBCC), Amsterdam, Netherlands, 9 - 11 March 2016, vol.57, (Summary Text)
23. Clinical and pathologic characteristics of patients with breast cancer and a second non-breast primary tumor.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)
24. Kişiye özel meme kanseri tedavisinde ki67 oranlarının Oncotype Dx skorlarıyla korelasyonu
18. Ulusal Cerrahi kongresi, İzmir, Turkey, 23 - 27 May 2012, (Summary Text)
25. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30, (Summary Text)
26. High Ki67 Values Are Significantly Correlated with Oncotype DX Scores
8th European Breast Cancer Conference (EBCC), Vienna, Austria, 21 - 24 March 2012, vol.48, (Summary Text)
29. Immunohistochemically Defined T1N0 Breast Cancer Subgroups Have Different Clinical Outcomes. A Retrospective Turkish Oncology Group Study
32nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 13 December 2009, vol.69, (Summary Text)
31. Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC)
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27, (Summary Text)
32. Results of randomized phase II trial combining Iressa (R) (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021.
31st Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 10 - 14 December 2008, vol.69, (Summary Text)
35. Stage I (T1N0M0) breast cancer (BC): Pathological characteristics and clinical outcome
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.113, (Summary Text)
36. Outcome of colon cancer patients receiving adjuvant chemotherapy in Marmara University Hospital
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.130, (Summary Text)
37. Outcome of metastatic colorectal cancer patients receiving palliative chemotherapy in Marmara University Hospital
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.129, (Summary Text)
38. Outcome of adjuvant treatment in turkish breast cancer (BC) patients (PTS): Single institution experience
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.109, (Summary Text)
39. Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.225-226, (Summary Text)
40. Association between presence of HPV DNA and P53 in breast cancer patients
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.110-111, (Summary Text)
41. Serum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab(T)-based therapy in metastatic breast cancer (MBC) patients (PTS). A Turkish oncology group study
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.90-91, (Summary Text)
42. Trastuzumab beyond progression in metastatic breast cancer
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.77, (Summary Text)
43. The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text)
44. Outcome of adjuvant treatment in elderly Turkish breast cancer patients.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text)
45. VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms): Relationship with pathological factors and prognostic impact on survival.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text)
46. Clinical and pathological characteristics of early breast cancer (EBC) patients < 35 years old.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text)
47. A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 8 - 11 December 2005, vol.94, (Summary Text)
48. Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: an analysis of 4,256 patients randomized in 12 trials
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 8 - 11 December 2005, vol.94, (Summary Text)
49. Human papilloma virus: Is it a new etiological factor in breast cancer?
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text)
50. The expression pattern of members of the EGFR signaling pathway and its relation with the duration of response in metastatic breast cancer (BC) patients (pts) treated with endocrine therapy (ET)
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text)
51. FOLFOX4 in metastatic colorectal cancer (MCRC) patients who progressed after infusional 5-FU/irinotecan based combination regimens.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text)
52. Prognostic value of thymidylate synthase and cox-2 expression in colorectal cancer patients' tumors.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text)
54. Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era.
25th San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 11 - 14 December 2002, vol.76, (Summary Text)
55. An EORTC IDBBC-ECSG randomized phase II trial of two different schedules of Caelyx (TM) in metastatic breast cancer patients.
25th San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 11 - 14 December 2002, vol.76, (Summary Text)
Books
10
Metrics
Publication
201
Open Access
10
UN Sustainable Development Goals
